CRISPR Therapeutics (NASDAQ:CRSP) Stock: Insider Simeon George Sells 14,514 Shares

CRISPR Therapeutics AG (NASDAQ:CRSP) Director Simeon George sold 14,514 shares of the stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $49.63, for a total transaction of $720,329.82. Following the completion of the sale, the director directly owned 15,486 shares of the company’s stock, valued at approximately $768,570.18. This trade represents a 48.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

CRISPR Therapeutics Price Performance

CRISPR Therapeutics stock traded down $2.27 during mid-day trading on Friday, hitting $49.25. The stock had a trading volume of 1,517,934 shares, compared to its average volume of 1,747,018. The firm’s 50 day moving average is $55.07 and its 200 day moving average is $53.24. CRISPR Therapeutics AG has a one year low of $44.12 and a one year high of $75.06. The firm has a market capitalization of $4.76 billion, a P/E ratio of -10.35 and a beta of 1.76. The company has a current ratio of 17.85, a quick ratio of 17.85 and a debt-to-equity ratio of 0.34.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Tuesday, June 30th. The company reported ($0.94) earnings per share (EPS) for the quarter. CRISPR Therapeutics had a negative return on equity of 24.39% and a negative net margin of 3,368.72%. The business had revenue of $10.18 million for the quarter. On average, sell-side analysts forecast that CRISPR Therapeutics AG will post -4.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CRISPR Therapeutics

Several large investors have recently made changes to their positions in the company. Versant Capital Management Inc lifted its position in shares of CRISPR Therapeutics by 175.1% in the second quarter. Versant Capital Management Inc now owns 465 shares of the company’s stock worth $25,000 after buying an additional 296 shares in the last quarter. Ameritas Advisory Services LLC purchased a new position in CRISPR Therapeutics during the 2nd quarter valued at approximately $56,000. GAMMA Investing LLC grew its holdings in CRISPR Therapeutics by 92.0% during the 3rd quarter. GAMMA Investing LLC now owns 1,246 shares of the company’s stock valued at $69,000 after buying an additional 597 shares in the last quarter. Hollencrest Capital Management increased its stake in CRISPR Therapeutics by 249.9% in the 1st quarter. Hollencrest Capital Management now owns 1,312 shares of the company’s stock worth $62,000 after acquiring an additional 937 shares during the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. increased its stake in CRISPR Therapeutics by 184.2% in the 2nd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,637 shares of the company’s stock worth $89,000 after acquiring an additional 1,061 shares during the last quarter. 69.20% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. HC Wainwright restated a “buy” rating on shares of CRISPR Therapeutics in a research note on Friday, October 9th. Wall Street Zen raised shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. UBS Group started coverage on shares of CRISPR Therapeutics in a research report on Thursday. They set a “neutral” rating and a $52.00 price objective on the stock. The Goldman Sachs Group reissued a “neutral” rating and issued a $55.00 target price on shares of CRISPR Therapeutics in a report on Thursday, August 6th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $82.00 target price on shares of CRISPR Therapeutics in a research note on Monday, August 31st. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $65.75.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing gene-editing medicines based on CRISPR/Cas9 technology. The company aims to treat serious diseases by precisely modifying genetic material in patients’ cells, with research programs spanning hematology, oncology, autoimmune diseases, and regenerative medicine.

Its lead product, CASGEVY (exagamglogene autotemcel), is a CRISPR/Cas9-based cell therapy developed with Vertex Pharmaceuticals. CASGEVY is approved in multiple markets, including the United States, United Kingdom, and European Union, for certain patients with sickle cell disease and transfusion-dependent beta thalassemia.